Canadian Securities ExchangeThe Daily Bell

ASEP Medical Holdings Inc. (CSE:ASEP) w/ Dr. Robert E.W. Hancock

July 13, 2023CSE Listed Issuer Updates

ASEP Medical Holdings Inc. (CSE:ASEP)

About This Video

Canadian Securities Exchange (CSE)'s Anil Mall recently caught up with Dr. Robert E.W. Hancock, CEO of ASEP Medical Holdings to discuss the company's holdings focused on addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine. In particular, Dr. Hancock discusses the preparation of an in vitro diagnostic test that helps assess the development of severe sepsis (i.e. blood poisoning) - a significant contributing factor in global deaths, including those from COVID-19.

Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.

thank you to our viewers who are tuning back into another CSE listed company update today I am talking to Dr Robert Hancock who is the CEO of ASAP medical Holdings Dr Hancock thank you so much for taking the time to join us today I hope you're well thank you it's a pleasure great hey I want to jump right into this tell us a little bit about the vision

behind ASAP medical Holdings what is you and your team working yeah so so a lot of people have talked about the this issue of infections of course infections are very top of our mind with the covert pandemic and it's recognized that there are real problems with treatment of infections as organisms become resistant to the drugs that we have available and so ASAP was built around that

concept and also around the concept that in the the current way that people treat infections for example bacterial infections with antibiotics is not working very well there's a there's a lot of a lot of failures with more than a million people dying every year just due to this resistance so ASAP basically just decided rather than try to narrow in on the problem they

Define the problem much more broadly so they defined it as this issue of antibiotic failure things where antibiotics fail and once you do that you start to bring in situations like sepsis which kills 20 percent of all people on the planner for which the major treatment is antibiotics obviously antibiotics fail pretty frequently there and also these types of infections called biofilm infections which are kind of bacteria bound to surfaces on the

body and forming these communities that are very very difficult to treat with antibiotics these are two really perilous situations for which we literally don't have any solutions at this stage and so we felt that was a good space for ASAP to be it I I love that Insight now I I've actually been to the website so I've read up a little bit on sepsis but for our viewers who might not be familiar

with this terminology can you maybe dive in a little bit and talk to us about what sepsis is why it's so important that you and your team are working to treat this yes so sepsis starts with an infection and it really is the body's abnormal response to that infection so rather than responding the way it's supposed to which is to mount a defense against the infection and kill the

invading organism the body starts to actually attack you you yourself the person who has the infection and so this is a kind of dysfunctional and dysregulated immune response is what is actually involved in sepsis and it causes organ dysfunction and organ failure so it's that's what eventually kills so many people got it I appreciate that Insight now I also notice you know before we jump

into your team and your background a little bit I've noticed that you've recently been ranked number four pardon me if I'm saying this incorrectly but rate number four microbiologists in the world by research.com is that correct yeah yeah I was a bit surprised when I got this email saying on the fourth best microbiologist in the world of course I don't really think about it that way but

this is for my academic career at the University of British Columbia and yeah I basically yeah but I'm rigged up there well hey you know congratulations for all of the hard work to be recognized there you've got a couple more accolades that are coming out recently but I want you to talk to our audience about your background how you got into this and what makes you so

passionate yeah so so researchers basically have to go out and find money that's not different from companies of course when we find money we write these proposals and at the end of The Proposal is what they call the significance section and the significant section says if I get this money I will do this this and this and of course in the area I work in which is trying

to deal with infections and this antibiotic value issue I say I'm going to try to overcome antibiotic failure and so I decided that I would take responsibility for the significant section and that's led me into my my other life which is involved with companies where we're actually not just providing Solutions but actually developing those Solutions commercially got it now what about your team did you

do you want to add to some of the team members you've brought on board to make this company a success yes so initially I have to talk about the team who are behind the actual research that led to the breakthroughs that involves more than a couple of hundred individuals 150 trainees people who did Doctorate Degrees or did post-doctoral studies with me and then

since then we've been able to amass really a wonderful bunch of individuals we have a medical director a Rob stanstrom who's a physician at Saint Paul's Hospital we have a chief scientific officer Dr Evan Haney who's a really good researcher in his own right and we have a whole bunch of people who've been able to support me in the business area where I feel like I'm less strong but

those individuals Tim Murphy Mike rore and many others have really helped to provide us with the tremendous impetus well said now 2023 has been a strong start for you and your team just based off the news that you and your team have been putting out consistently can you talk to us a little bit about some of the JVS that you and your team have signed this year

yes so we so we've actually signed a JV with a Google c-spring in Bahrain this is to take our sepsis diagnostic which we're going to try to bring to maturity in North America sometime early next year maybe maybe q1 2024 that's a really aggressive development so this c-spring we formed a joint venture in Bahrain that covers and with the prince of

Bahrain as it turns out that covers North America and Middle East and basically will allow us to create marketplaces in this other area we've also signed a term sheet for JB and China that will also allow us to develop the Chinese area this allows us to really diversify a market potential and will bring us income in areas where we just don't have marketing apparatus to move forwards so

that's been a lot of it although we also have a bunch of Partnerships on the other side of our company which is developing therapies for bioform infections so we have a strong relationship with a U.S company called ifiber and we're developing other relationships especially in wound healing and oral health okay and and your team has just recently completed a clinical study as well can

you talk to us about that and what the process was that goes into it so a lot of people when they develop a diagnostic go in Fairly blind and that means that the clerk their formal Club was study the one that is insisted upon by the regulatory authorities they don't really know what the result will be so we've performed a very large clinical study of a million

thousand patients now where we demonstrated that our diagnostic assay worked really well we've also analyzed other literature or other data sets that are present in developed by other people and so we have a total of 2140 patients worth of data already amassed demonstrating that our diagnostic really shoots everything else around there out of the water so the the nice thing about this is

it's enabled us to move back the time where our diagnostic can be applied so it can we know that it can be applied immediately a patient hits the emergency room we'll perhaps when they first go into the ICU and early treatment of sepsis is critical because for every our you to lay appropriate therapy there's a like an eight percent increased risk of death well allowed us to take the

signature which is originally quite large and narrow it down to a very modest number of genes and that makes it a lot more practical to develop so this these two things have happened because we've been able to get a large number of patients and then critically in this large set of studies we have data from four different no five different countries and four different consonants so we know that our test Works in

diverse sets of individuals wonderful now for for our viewers shareholders anyone that might be on the sidelines what would you see is is key to paying attention to what you and your team are working on at Asa yes so I think that the big thing is that we're dealing with extremely large and unsatisfied markets so on the one hand with the diagnostic area we're dealing with sepsis so it's there are 49

million people acquired sepsis in the last year they counted 2017 and 11 billion people of those died so it's a a course of 20 of all deaths on the planet and we desperately need early warning Diagnostics and that's what ASAP will provide in addition we had a little disease I'm sure nobody's heard about called covert 19. and covid-19 caused 18 million access this on the

planet just a couple of years and it turns out that everybody who dies from covid-19 died from sepsis so sepsis is the actual cause of death so over and above just the organism the real cause of death eventually is this immune dysfunction you know caused by that that results in sepsis so that's one side so on the other side on the therapeutic side we're dealing with biofilm infections and

there was a review came out recently that said this is a 385 billion dollar problems at the medical system worldwide and really there are no there's actually no approved drugs for this area this is a great unsatisfied Market into which sepsis can enter into which ASAP can enter so we've got these large unsatisfied markets that I think we're addressing and that gives us just a massive potential

and so where can our viewers go to read up more not only on sepsis but to read up on your background the team and and obviously sign up for your upcoming press releases so they can be in the know absolutely so we have a we have a website and if you just type in ASAP you'll find it or ASAP medical if you want to look up me personally

just type my name Robert E W Hancock into the internet you'll find my web my University website that tells you all about the background on the sites the type of stuff about that and then if you type in that you'll also find quite a few things that I've done along the way television interviews and radio interviews and such like that really will have made a a huge difference no

worries I I actually encourage our viewers to go to your website read up on what your team is working on to do their due diligence on behalf of the CSC though I want to thank you for your time and especially congratulate you on the recent Accolade of of being ranked number four microbiologist in in in the world well to everybody watching you've been listening to Dr Robert

Hancock he is the CEO of ASAP medical Holdings Amber Neil Mal representing the Canadian Securities Exchange and I thank everyone for their time thank you Dr Hancock thanks so much

thank you

More CSE Listed Issuer Updates

See them all

Critical One Energy (CSE:CRTL)The Race for AntimonyNov 5, 2026
Hillcrest Energy (CSE:HEAT)Powering the Future with 99.7% EfficiencyOct 21, 2026
Nerds On Site (CSE:NERD)Profitability, Expansion & AISep 16, 2026
Purecore Metals (CSE:PURE)Uranium, Copper & Rising Power DemandSep 15, 2026